{"id":"NCT00396877","sponsor":"Sanofi","briefTitle":"Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation","officialTitle":"International Randomized Double Blind Study Evaluating the Efficacy and the Safety of Clopidogrel 0.2 mg/kg Once Daily Versus Placebo in Neonates and Infants With Cyanotic Congenital Heart Disease Palliated With Systemic to Pulmonary Artery Shunt","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2010-02","completion":"2010-02","firstPosted":"2006-11-08","resultsPosted":"2011-03-11","lastUpdate":"2014-10-24"},"enrollment":906,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Heart Defects, Congenital"],"interventions":[{"type":"DRUG","name":"Clopidogrel (SR25990)","otherNames":["Plavix"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Clopidogrel 0.2 mg/kg/day","type":"EXPERIMENTAL"}],"summary":"Contemporary management of cyanotic congenital heart disease includes three stages of surgery. Incidence of shunt thrombosis and death between the two first stages of palliation remains important.\n\nThe primary objective of the study is to evaluate the efficacy of Clopidogrel 0.2 mg/kg/day for the reduction of all cause mortality and shunt related morbidity in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt (e.g. modified Blalock Taussig Shunt \\[BTS\\]).\n\nThe secondary objective was to assess the safety of Clopidogrel in the study population.","primaryOutcome":{"measure":"Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure < 120 Days Considered of Thrombotic Nature)","timeFrame":"Median follow-up of 5.8 months (up to a maximum of 12 months after randomization)","effectByArm":[{"arm":"Placebo","deltaMin":90,"sd":null},{"arm":"Clopidogrel 0.2 mg/kg/Day","deltaMin":89,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4340"}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":31,"countries":["United States","Argentina","Belgium","Brazil","Canada","China","Denmark","Egypt","Finland","France","Germany","Hong Kong","Hungary","India","Israel","Italy","Malaysia","Mexico","Netherlands","Norway","Poland","Portugal","Russia","Singapore","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["23782178"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":196,"n":436},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","VOMITING","NASOPHARYNGITIS","DIARRHOEA"]}}